Science news and articles on health, environment, global warming, stem cells, bird flu, autism, nanotechnology, dinosaurs, evolution -- the latest discoveries in astronomy, anthropology, biology, chemistry, climate & bioengineering, computers, engineering ; medicine, math, physics, psychology, technology, and more from the world's leading research centers universities.

RIKEN enters collaboration with Grace Science Foundation for research on NGLY1

0

RIKEN has entered into a collaboration with the Grace Science Foundation to conduct research on NGLY1 deficiency, a rare genetic disorder that was discovered in 2012 by American doctors. NGLY1 deficiency, which is thought to be caused by a deficiency in N-glycanase-1, an enzyme encoded by the gene NGLY1, is characterized by a variety of symptoms, including global developmental delay, movement disorder, seizures, and ocular abnormalities. It is an extremely rare disorder, with less than 50 known cases in the world today.

Under the collaboration, the Grace Science Fund at the San Francisco Foundation will provide support and funding to RIKEN to gain a better understanding of NGLY1 deficiency and to look for potential therapeutic targets. Tadashi Suzuki, who is spearheading the research efforts at the RIKEN-Max Planck Joint Research Center in Japan, first identified N-glycanase-1 in mammals two decades ago. Suzuki recently discovered that a second enzyme, endo-β-N-acetylglucosaminidase (ENGase), may also be a potential therapeutic target. The project is also being supported by Hiroshi Mikitani, President and CEO of Rakuten, a major electronic commerce and internet company.

According to Matt Wilsey, President and Co-founder of the Grace Science Foundation,"I have been very impressed by Dr. Suzuki's 20+ years of research. I believe this collaboration with the Suzuki Lab and RIKEN will bring us closer to a cure for NGLY1 and other metabolic diseases."

According to Suzuki, "We appreciate the support from the Grace Science Fund at the San Francisco Foundation,. The Grace Science team is leading the charge to find a cure for NGLY1 deficiency. I have long been interested in N-glycanase-1, and it is a privilege that my work has been recognized as being important for the potential cure of a serious genetic condition."

###

About RIKEN

RIKEN is Japan's largest research institute for basic and applied research. Over 2500 papers by RIKEN researchers are published every year in leading scientific and technology journals covering a broad spectrum of disciplines including physics, chemistry, biology, engineering, and medical science. RIKEN's research environment and strong emphasis on interdisciplinary collaboration and globalization has earned a worldwide reputation for scientific excellence.
Homepage: http://www.riken.jp/en/
Follow us on Facebook at http://www.facebook.com/RIKEN.english
Find us on Twitter at @riken_en

About the Grace Science Foundation

Kristen and Matt Wilsey founded the Grace Science Foundation when their daughter Grace was diagnosed with a rare genetic disease called NGLY1 deficiency. This complex and devastating neuromuscular disease affected less than 5 known patients worldwide at the time. Very few resources existed that were devoted to NGLY1 deficiency, either in terms of funding, public awareness, active research or existing knowledge. Undeterred, the Wilseys decided to apply their passion and entrepreneurial spirits to finding a cure for Grace and other NGLY1 deficiency patients. Over the last 6+ years, the foundation has assembled a world-class team of over 75 scientists across 20 teams in the United States, Canada, Italy, Germany, and Japan. They work not only to understand the disease and develop a cure, but also to drive innovations in the world of genetic research in general. Their work has been featured by CNN.com, the San Francisco Chronicle, Der Spiegel, and the New Yorker. To learn more, please visit http://www.gracescience.org.

Media Contact

Jens Wilkinson
jens.wilkinson@riken.jp
81-484-621-225
@riken_en

http://www.riken.jp/en/

Leave A Reply

Your email address will not be published.